SCHEMBL615545

SCHEMBL615545

Cc1c2cc[nH]c(=O)c2cc2c1[nH]c1ccc(OCc3ccccc3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.53
MAOB P27338 2/20 0.53
CTSV O60911 3/20 0.48
CTSL P07711 3/20 0.48
IP6K1 Q92551 1/20 0.48
LIMK1 P53667 1/20 0.48
LIMK2 P53671 1/20 0.48
TRPM8 Q7Z2W7 1/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GABRA1 P14867 1/20 0.47
GABRG2 P18507 1/20 0.47
GABRB3 P28472 1/20 0.47
GABRA5 P31644 1/20 0.47
GABRA3 P34903 1/20 0.47
GABRA2 P47869 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614498 0.84 LIMK1 (0.67) MAOAMAOBCTSVCTSLIP6K1
SCHEMBL11077910 0.82 STING1 (0.54) LIMK1LIMK2KDM4EMAPTLMNA
SCHEMBL7899171 0.80 LIMK1 (0.56) MAOAMAOBCTSVCTSLLIMK1
SCHEMBL614042 0.79 MAOA (0.55) MAOAMAOBCTSVCTSLTRPM8
SCHEMBL613815 0.78 MAOA (0.54) MAOAMAOBTRPM8KDM4EMAPT
SCHEMBL11081378 0.78 NQO2 (0.51) LIMK1LIMK2KDM4EMAPTLMNA
SCHEMBL10022323 0.73 MAOA (0.47) MAOAMAOBCTSVCTSLTRPM8
SCHEMBL5504619 0.73 KDM4E (0.69) MAOAMAOBCTSVCTSLTRPM8
SCHEMBL18796679 0.73 MAOA (0.62) MAOAMAOBCTSVCTSLTRPM8
SCHEMBL5879186 0.72 MAOA (0.58) MAOAMAOBCTSVCTSLIP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604048-B2 Pyridocarbazole type compounds and applications thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
WO-2010095042-A2 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF NLN, OPA1, PYCR1 MAOA 331/4885MAOB 248/4885CTSV 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.